SXTC
China SXT Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CN
$2.23
+1.36%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5M | 1.1M | 1.7M | 1.9M | 2.0M |
| Cost of Revenue | 1.4M | 889.4K | 1.4M | 1.4M | 1.5M |
| Gross Profit | 1.1M | 183.3K | 367.4K | 554.0K | 426.3K |
| Operating Expenses | |||||
| R&D Expense | — | 178.8K | 191.4K | 184.2K | — |
| SG&A Expense | 9.4M | 7.1M | 3.0M | 3.1M | 6.0M |
| General & Admin Expense | 8.5M | 7.1M | 2.8M | 2.6M | 5.6M |
| Selling & Marketing Expense | 909.4K | — | 289.9K | 433.6K | 387.5K |
| Other Expenses | 244.0K | — | (191.4K) | (184.2K) | — |
| Total Operating Expenses | 9.7M | 7.3M | 3.0M | 3.1M | 6.0M |
| Cost and Expenses | 11.1M | 8.2M | 4.4M | 4.4M | 7.6M |
| Operating Income (EBIT) | (8.5M) | (7.1M) | (2.7M) | (2.5M) | (5.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 311.7K | 63.0K | 648.2K | 544.3K | 476.8K |
| Net Interest Income | (311.7K) | (63.0K) | (648.2K) | (544.3K) | (476.8K) |
| Other Non-Op Income/Expense | (211.7K) | 1.0M | (623.2K) | (583.3K) | (327.3K) |
| Non-Operating Income (excl Interest) | — | — | (25.0K) | 39.0K | (149.5K) |
| EBT (Pre-Tax Income) | (8.7M) | (6.1M) | (3.3M) | (3.1M) | (5.9M) |
| Income Tax Expense | (1.4M) | 130.8K | — | — | — |
| Bottom Line | |||||
| Net Income | (7.4M) | (6.2M) | (3.3M) | (3.1M) | (5.9M) |
| Earnings from Cont. Ops | (7.4M) | (6.2M) | (3.3M) | (3.1M) | (5.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.4M) | (6.2M) | (3.3M) | (3.1M) | (5.9M) |
| Per Share | |||||
| Basic EPS | ($8.46) | ($9.13) | ($8.18) | ($3.57) | ($22.23) |
| Diluted EPS | ($8.46) | ($9.13) | ($8.18) | ($3.57) | ($22.23) |
| Revenue Per Share | $4.33 | $1.58 | $4.31 | $2.22 | $7.39 |
| Shares | |||||
| Basic Shares Outstanding | 585774 | 679648 | 403920 | 867422 | 266973 |
| Diluted Shares Outstanding | 585774 | 679648 | 403920 | 867422 | 266973 |
| Profitability Metrics | |||||
| EBITDA | (8.4M) | (7.0M) | (2.6M) | (2.4M) | (5.2M) |
| D&A | 170.9K | 143.2K | 82.3K | 203.2K | 250.2K |
| EBIT | (8.5M) | (7.1M) | (2.7M) | (2.6M) | (5.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026